Is GTBIF a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Green Thumb Industries (GTBIF) rests on Federal rescheduling and the end of 280E: The single largest driver is federal policy. The bear case rests on the main risk is regulatory. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

GTBIF key stats

At $5.51 on November 20, 2026, Green Thumb Industries (GTBIF) has a market cap of $1.2B and a P/E of 13.1 on trailing earnings (21.2 on forward earnings).

Market cap
$1.2B
P/E (trailing)
13.1
P/E (forward)
21.2
EPS (trailing 12 months)
$0.42
Price to book
0.6
Beta
1.14

Market cap, P/E and yield are measured at the $5.51 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Green Thumb Industries (GTBIF)?

The last two weeks for Green Thumb Industries, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • GTBIF closed at $5.51 on November 20, 2026, down 10.0% over the past five trading days (from $6.12).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. It grows, processes and sells cannabis under consumer brands such as Rythm (flower and vapes), Dogwalkers (pre-rolls), incredibles (edibles) and Beboe, and it runs roughly 100 to 115 RISE and other branded dispensaries across 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut and Nevada. Because cannabis remains federally illegal for adult use, its shares cannot list on a US exchange: they trade over the counter as GTBIF and on the Canadian Securities Exchange as GTII. The business has been steady, not fast-growing. Full-year 2025 revenue was ~$1.18B, up ~3.4%, with GAAP net income of ~$114M (helped by warrant fair-value gains) and ~$295M of operating cash flow. In Q2 2026, revenue rose ~4.6% to ~$306.7M and GAAP net income was only ~$4.9M. Q3 2026, reported November 4, was a step up on the top line: revenue rose ~11% to ~$324.4M, driven by Minnesota adult-use retail and existing markets, and comparable-store sales grew ~3%, the first positive comp since Q3 2024. Normalized EBITDA was ~$89M (~28% of revenue) and operating cash flow ~$58M. Gross margin held near ~45%, down from ~49% a year earlier, with ~$15.8M of brand licensing fees a major factor, and SG&A rose to ~$122M. The company posted a GAAP net loss of ~$4.8M, ending its run of profitable quarters, while adjusted EPS of ~$0.07 beat the ~$0.04 consensus. Cash rose to ~$316M. Management guided fourth-quarter revenue flat to slightly down sequentially and expects further margin compression. The investment picture is a contest between solid fundamentals and a hostile structure. In April 2026, the Justice Department moved state-licensed medical marijuana into Schedule III, which ended the punitive Section 280E tax on parts of Green Thumb's business and cut its Q2 tax bill to ~$12.5M from ~$21.6M. Adult-use cannabis still sits in Schedule I, so most of the revenue base still faces 280E and banking limits, and management warned on the Q3 call that delays in broader rescheduling mean continued significant tax liabilities. Bulls point to a ~13.5x trailing earnings multiple, EV/EBITDA under 6x, a large cash balance, Florida store openings and upside from broader rescheduling or new states such as Virginia and Texas. Skeptics point to years of falling prices, a forward P/E near 22x on lower expected earnings, and the risk that policy relief stays partial. As of November 20, 2026 the shares closed at ~$5.69, down ~30% year to date but up ~8% over a year.

The bull case for GTBIF

1. Federal rescheduling and the end of 280E

The single largest driver is federal policy. The April 2026 order placed state-licensed medical marijuana in Schedule III, and Green Thumb says Section 280E stopped applying to those operations from April 28, 2026. That was visible right away: Q2 income tax expense fell to ~$12.5M from ~$21.6M. Adult-use sales, which are most of the company's revenue, still fall under Schedule I, and a broader administrative hearing ran from late June into July 2026 without a final decision by the Q3 call in November. If adult-use cannabis is also moved to Schedule III, Green Thumb would stop paying tax on gross profit and pay it on net income, which could add tens of millions of dollars a year to free cash flow and could narrow the discount to ordinary consumer companies. Management has said it is not interested in uplisting or restructuring the business until scheduling and tax clarity improve.

2. New adult-use markets and store openings in its footprint

Green Thumb's growth has come in steps each time a state it already serves converts from medical to adult-use. Minnesota is the current example: its eight RISE dispensaries switched to adult-use in September 2025 and drove much of the ~11% Q3 2026 revenue growth, though management now expects that market to lean more toward wholesale as competing stores open. The company plans 3-5 new Florida stores before year-end 2026 and 10 or more in 2027, plus 1-2 in Ohio. Virginia adult-use sales are scheduled to begin July 1, 2027, where the company has invested heavily, and in Texas it holds a conditional license under the Compassionate Use Program and recently bought a facility outside Fort Worth, though timing there is uncertain. Pennsylvania and Florida remain medical-only and are the largest potential prizes.

3. Brand strength and wholesale share

Unlike many operators that rely mostly on their own stores, Green Thumb sells heavily through third-party dispensaries. On the Q3 2026 call management said Rythm ranked first nationally in branded flower and Dogwalkers first in uninfused pre-rolls, and incredibles is a leading edibles name in several states. Brand pull matters because flower prices keep falling: the company's gross margin slid from ~52.9% in 2024 to ~48.9% in 2025 and ~45% in Q2 and Q3 2026. A strong brand portfolio gives some pricing support and shelf space when competitors discount. It also positions the company for a future in which interstate commerce is permitted, since national brands would travel more easily than local ones.

4. Capital returns and balance sheet strength

Green Thumb is one of the few cannabis companies that generates enough cash to return it. Operating cash flow was ~$295M in 2025 and ~$253M over the trailing twelve months to September 2026. The board expanded its buyback to a $150M maximum in April 2026, and in the first half of 2026 the company repurchased ~13.4M shares at an average of ~$5.78, bringing cumulative buybacks to ~29.5M shares for ~$203M. Cash rose to ~$316M at September 30, 2026. Yahoo Finance reports total debt of ~$554.5M, a figure that can include lease liabilities, so the balance sheet is less net-cash than the ~$283M of debt the company cited at June 30 suggests. Management describes itself as cautious on M&A, which leaves room for store openings and buybacks without diluting shareholders.

The bear case for GTBIF

The main risk is regulatory. Adult-use cannabis remains a Schedule I substance, so most of Green Thumb's sales still face Section 280E, restricted banking and no access to US stock exchanges. A broader rescheduling decision could be delayed, narrowed or challenged in court, the IRS has not issued complete guidance on how the April 2026 order applies, and management has warned that delays mean continued significant tax liabilities. Price compression is the second risk: gross margin fell roughly eight points in two years to ~45% in Q3 2026, management expects further compression in coming quarters, and new cultivation capacity in states like Illinois, New Jersey and Ohio continues to push prices down. Third, intoxicating hemp-derived THC products, now sold in mainstream retailers, compete for the same customers without cannabis licensing costs or taxes, although management said changes in hemp policy could become a tailwind. Fourth, profitability is lumpy: 2025 GAAP net income leaned on warrant fair-value gains, Q2 2026 GAAP net income was only ~$4.9M, and Q3 2026 was a GAAP net loss of ~$4.8M as SG&A rose. Consensus expects 2026 EPS of only ~$0.11 before a rebound to ~$0.36 in 2027, so the forward multiple depends on that recovery. Finally, GTBIF trades OTC with lower liquidity and higher volatility than listed stocks, many US brokers restrict cannabis names, analyst coverage on Yahoo Finance is thin (two analysts), and founder voting control limits outside shareholder influence. Growth also depends on a short list of state catalysts: Virginia adult-use is not scheduled until mid-2027, Texas timing is uncertain, and Pennsylvania and Florida have repeatedly stalled on adult-use legalization.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding GTBIF already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on GTBIF

Too few analysts publish on GTBIF for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The GTBIF forecast page covers what coverage does exist.

How is GTBIF valued?

Market cap, P/E and dividend yield at today's price are in the GTBIF key stats above. The business figures below come from Green Thumb Industries's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.24B; Q3 2026 ~$324.4M, up ~11%
  • Net income (TTM): ~$98.7M (~7.9% margin); Q3 2026 GAAP loss ~$4.8M
  • Q3 2026 adjusted EPS: ~$0.07 vs ~$0.04 expected
  • Q3 2026 gross margin: ~45% (vs ~49% a year earlier)
  • Cash / total debt: ~$316M / ~$554.5M (Yahoo, Sept 30, 2026)

As of November 2026: At ~$5.69, Green Thumb is valued at roughly 1.0 times trailing sales and about 13.5 times trailing earnings, with enterprise value under six times trailing EBITDA. The forward P/E is higher, near 22x, because consensus expects 2026 EPS of only ~$0.11 before ~$0.36 in 2027. Those multiples are low for a company with ~28% normalized EBITDA margins and positive cash flow, and the gap reflects federal illegality, 280E taxes, OTC-only trading in the US and steady price compression. The next data points are a federal rescheduling decision and the Q4 2026 report, where management has guided revenue flat to slightly down sequentially (consensus ~$323.5M).

How do you decide if GTBIF is a buy?

Whether GTBIF is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold GTBIF indirectly through an index or sector ETF before adding more.

What would change your mind on GTBIF

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Federal rescheduling and the end of 280E stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the main risk is regulatory fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the GTBIF stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GTBIF against your real portfolio and see your actual exposure before deciding.

Your questions about Green Thumb Industries

Ask Walnut's AI anything about GTBIF and see how it fits what you own.

FAQ

Is GTBIF a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Federal rescheduling and the end of 280E, with revenue (ttm) at ~$1.24B; Q3 2026 ~$324.4M, up ~11%. The bear case rests on the main risk is regulatory. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell GTBIF?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The main risk is regulatory. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.

What is the bull case for GTBIF?

+

Federal rescheduling and the end of 280E. The single largest driver is federal policy.

What is the bear case for GTBIF?

+

The main risk is regulatory. Adult-use cannabis remains a Schedule I substance, so most of Green Thumb's sales still face Section 280E, restricted banking and no access to US stock exchanges. A broader rescheduling decision could be delayed, narrowed or challenged in court, the IRS has not issued complete guidance on how the April 2026 order applies, and management has warned that delays mean continued significant tax liabilities. Price compression is the second risk: gross margin fell roughly eight points in two years to ~45% in Q3 2026, management expects further compression in coming quarters, and new cultivation capacity in states like Illinois, New Jersey and Ohio continues to push prices down. Third, intoxicating hemp-derived THC products, now sold in mainstream retailers, compete for the same customers without cannabis licensing costs or taxes, although management said changes in hemp policy could become a tailwind. Fourth, profitability is lumpy: 2025 GAAP net income leaned on warrant fair-value gains, Q2 2026 GAAP net income was only ~$4.9M, and Q3 2026 was a GAAP net loss of ~$4.8M as SG&A rose. Consensus expects 2026 EPS of only ~$0.11 before a rebound to ~$0.36 in 2027, so the forward multiple depends on that recovery. Finally, GTBIF trades OTC with lower liquidity and higher volatility than listed stocks, many US brokers restrict cannabis names, analyst coverage on Yahoo Finance is thin (two analysts), and founder voting control limits outside shareholder influence. Growth also depends on a short list of state catalysts: Virginia adult-use is not scheduled until mid-2027, Texas timing is uncertain, and Pennsylvania and Florida have repeatedly stalled on adult-use legalization.

What does Green Thumb Industries do?

+

Chicago-based multi-state cannabis operator with RISE dispensaries and consumer brands in 14 markets.

What would have to change for GTBIF to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Federal rescheduling and the end of 280E) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the main risk is regulatory) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Green Thumb Industries do?

+

Green Thumb Industries is a vertically integrated US cannabis company. It cultivates and processes cannabis in licensed facilities, makes branded products such as Rythm flower and vapes, Dogwalkers pre-rolls, incredibles edibles and Beboe, and sells them both through its own dispensaries (mostly under the RISE name) and wholesale to other licensed stores. It operates in 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut, Massachusetts, Maryland, Nevada and New York, with roughly 100 to 115 stores. The company is headquartered in Chicago, was founded in 2014 by CEO Ben Kovler, and generated ~$1.24B of revenue over the trailing twelve months to September 2026.

Why does GTBIF trade over the counter instead of on the NYSE or Nasdaq?

+

US stock exchanges will not list companies that touch cannabis that remains illegal under federal law, and adult-use cannabis is still a Schedule I substance. Green Thumb therefore lists on the Canadian Securities Exchange as GTII and trades in the US on the OTC market as GTBIF. That has practical effects: lower liquidity, wider bid-ask spreads, exclusion from major indexes and many institutional mandates, and the fact that some US brokerages and custodians restrict buying cannabis stocks altogether. Many observers attribute part of the sector's low valuation to this structure. A federal change that allowed uplisting to a major US exchange would likely broaden the shareholder base, though timing is uncertain, and management said in November 2026 it is not pursuing an uplisting until federal scheduling and tax treatment are clearer.

How did Green Thumb perform in its most recent quarter?

+

In Q3 2026, reported November 4, revenue rose ~11% year over year to ~$324.4M, led by Minnesota adult-use retail, and comparable-store sales grew ~3%, the first positive comp since Q3 2024. Gross margin was ~45%, down from ~49%, and SG&A rose to ~$122M. The company posted a GAAP net loss of ~$4.8M, but adjusted EPS of ~$0.07 beat the ~$0.04 consensus and normalized EBITDA was ~$89M, about 28% of revenue. Cash ended at ~$316M. Management guided Q4 revenue flat to slightly down and expects more margin compression.

Walnut is informational, not investment advice, and gives no verdict on GTBIF. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks